However, the intriguing findings of clinical benefit in high-proliferative hormone receptor-positive disease along with preliminary data of immunotherapeutic benefit in metastatic HER2-positive disease [39] highlight the interest to further evaluate the role of immunotherapy in other breast cancer subtypes. Here, ERBB2 is linked to breast carcinoma.